Tropical disease vaccines

A Dengue virus (DENV) messenger ribonucleic acid (mRNA) vaccine, comprising:

• at least one mRNA polynucleotide comprising an open reading frame encoding at least one DENV antigenic polypeptide or an immunogenic fragment thereof, wherein 100% of the uracil in the open reading frame have a chemical modification and wherein the chemical modification is a N1-methylpseudouridine;
• and
• a lipid nanoparticle comprising a compound of Formula (I):
• wherein:
• R1 is selected from the group consisting of C5-30 alkyl, C5-20 alkenyl, and —R″M′R′;
• R2 and R3 are independently selected from the group consisting of C1-14 alkyl and C2-14 alkenyl;
• R4 is —(CH2)nQ, wherein Q is —OR, and n is selected from 1, 2, 3, 4, and 5;
• each R5 is H;
• each R6 is H;
• M and M′ are independently selected from —C(O)O— and —OC(O)—;
• R7 is H;
• R is H;
• R′ is selected from the group consisting of C1-18 alkyl and C2-18 alkenyl;
• R″ is selected from the group consisting of C3-14 alkyl and C3-14 alkenyl;
• and
• m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.